Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Posttransplant Cyclophosphamide as GVHD Prophylaxis in AML Pediatric Patients Undergoing Allogeneic HSCT

Andra Marcu,Ana Bica,Cristina Jercan,Andreea Serbanica,Letitia Radu,Alexandra Ionete,Oana Grigoras,Codruta Popa,Carmen Calugaroiu,Constantin Arion,Anca Colita

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2019）

Cited 0|Views2
No score
Abstract
Use of cyclophosphamide (PTCy) after allogeneic hematopoietic stem cell transplantation (HSCT) as graft versus host disease (GVHD) prophylaxis has lately become frequent since GVHD is the main cause of non-relapse mortality (NRM) after transplantation. Cy is known to selectively destroy alloreactive T lymphocytes, clonal depletion and inducing immune tolerance.
More
Translated text
Key words
acute myeloblastic leukemia,allogeneic hematopoietic stem cell transplantation,graft versus host disease,cyclophosphamide,AML,acute myeloid leukemia
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined